Randomized Placebo-Controlled Trial of Ursodeoxycholic Acid With Vitamin E in Nonalcoholic Steatohepatitis

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 12, 2006, Pages 1537-1543

  Dufour, Jean François ^a   Oneta, Carl M ^b   Gonvers, Jean Jacques ^b   Bihl, Florian ^c   Cerny, Andreas ^c   Cereda, Jean Michel ^d   Zala, Jean Franco ^e   Helbling, Beat ^f   Steuerwald, Michael ^g   Zimmermann, Arthur ^h  

^a UNIVERSITY OF BERN   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c Hospital of Lugano   (Switzerland)

^d Department of Gastroenterology   (Switzerland)

^e Hospital Chur   (Switzerland)

^f Hospital of St Gallen   (Switzerland)

^g Hospital of Liestal   (Switzerland)

^h UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FATTY LIVER; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; LIVER BIOPSY; LIVER HISTOLOGY; MALE; MULTICENTER STUDY; NONALCOHOLIC FATTY LIVER; PATHOLOGIST; RANDOMIZED CONTROLLED TRIAL; REMISSION;

ADOLESCENT; ADULT; AGED; BIOPSY; CHOLAGOGUES AND CHOLERETICS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSAMINASES; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID; VITAMIN E; VITAMINS;

EID: 33845336554     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.09.025     Document Type: Article

References (29)

1. Caldwell S.H., Oelsner D.H., Iezzoni J.C., et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29 (1999) 664-669
2. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999) 1413-1419
3. Oneta C., and Dufour J.-F. Treatment options in non-alcoholic steatohepatitis according to pathogenic considerations. Swiss Med Wkly 132 (2002) 493-505
4. Paumgartner G., and Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis 8 (2004) 67-81 vi
5. Laurin J., Lindor K.D., Crippin J.S., et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23 (1996) 1464-1467
6. Lindor K.D., Kowdley K.V., Heathcote E.J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39 (2004) 770-778
7. Strauss R. Comparison of serum concentrations of alpha-tocopherol and beta-carotene in a cross-sectional sample of obese and nonobese children (NHANES III). J Pediatr 134 (1999) 160-165
8. Hasegawa T., Yoneda M., Nakamura K., et al. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15 (2001) 1667-1672
9. Harrison S.A., Torgerson S., Hayashi P., et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98 (2003) 2485-2490
10. Promrat K., Lutchman G., Uwaifo G.I., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39 (2004) 188-196
11. Ueno T., Sugawara H., Sujaku K., et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27 (1997) 103-107
12. Suzuki A., Lindor K., St Saver J., et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 43 (2005) 1060-1066
13. Bugianesi E., Gentilcore E., Manini R., et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100 (2005) 1082-1090
14. Sanyal A.J., Mofrad P.S., Contos M.J., et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2 (2004) 1107-1115
15. Kugelmas M., Hill D.B., Vivian B., et al. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38 (2003) 413-419
16. Seki S., Kitada T., Yamada T., et al. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 37 (2002) 56-62
17. Chalasani N., Deeg M.A., and Crabb D.W. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 99 (2004) 1497-1502
18. Browning J.D., and Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114 (2004) 147-152
19. James O., and Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 353 (1999) 1634-1636
20. George D., Goldwurm S., MacDonald G., et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114 (1998) 311-318
21. Bonkovsky H.L., Jawaid Q., Tortorelli K., et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 31 (1999) 421-429
22. Feldstein A.E., Canbay A., Angulo P., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125 (2003) 437-443
23. Fromenty B., Robin M.A., Igoudjil A., et al. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab 30 (2004) 121-138
24. Rodrigues C.M., and Steer C.J. The therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent. Expert Opin Investig Drugs 10 (2001) 1243-1253
25. Rodrigues C.M., Fan G., Wong P.Y., et al. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 4 (1998) 165-178
26. Rodrigues C.M., Fan G., Ma X., et al. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 101 (1998) 2790-2799
27. Ratziu V., Charlotte F., Heurtier A., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128 (2005) 1898-1906
28. Brunt E.M., Janney C.G., Di Bisceglie A.M., et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. [in process citation]. Am J Gastroenterol 94 (1999) 2467-2474
29. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321